Aller au contenu principal

 Articles scientifiques

Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: lessons from the PEARL study.

Auteurs : Agostinetto E, Ignatiadis M
Année : 2021
Journal : Ann Oncol
Volume : 32
Pages : 427-430

Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts.

Auteurs : Stacchiotti S, Miah AB, Frezza AM, Messiou C, Morosi C, Caraceni A, Antonescu CR, Bajpai J, Baldini E, Bauer S, Biagini R, Bielack S, Blay JY, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Callegaro D, de Alava E, Deoras-Sutliff M, Dufresne A, Eriksson M, Errani C, Fedenko A, Ferraresi V, Ferrari A, Fletcher CDM, Garcia Del Muro X, Gelderblom H, Gladdy RA, Gouin F, Grignani G, Gutkovich J, Haas R, Hindi N, Hohenberger P, Huang P, Joensuu H, Jones RL, Jungels C, Kasper B, Kawai A, Le Cesne A, Le Grange F, Leithner A, Leonard H, Lopez Pousa A, Martin Broto J, Merimsky O, Merriam P, Miceli R, Mir O, Molinari M, Montemurro M, Oldani G, Palmerini E, Pantaleo MA, Patel S, Piperno-Neumann S, Raut CP, Ravi V, Razak ARA, Reichardt P, Rubin BP, Rutkowski P, Safwat AA, Sangalli C, Sapisochin G, Sbaraglia M, Scheipl S, Schöffski P, Strauss D, Strauss SJ, Sundby Hall K, Tap WD, Trama A, Tweddle A, van der Graaf WTA, Van De Sande MAJ, van Houdt W, van Oortmerssen G, Wagner AJ, Wartenberg M, Wood J, Zaffaroni N, Zimmermann C, Casali PG, Dei Tos AP, Gronchi A
Année : 2021
Journal : ESMO Open
Volume : 6
Pages : 100170

Debating Pros and Cons of Total Neoadjuvant Therapy in Rectal Cancer.

Auteurs : Sclafani F, Corrò C, Koessler T
Année : 2021
Journal : Cancers (Basel)
Volume : 13

Sarcoidosis Versus Lymphoma?

Auteurs : Dal Lago L, Sarrand J, Woff E, Awada A, Vouche M, Pepersack T
Année : 2021
Journal : Eur J Case Rep Intern Med
Volume : 8
Pages : 002250

Cell-free circulating tumor DNA profiling in cancer management.

Auteurs : Roy D, Lucci A, Ignatiadis M, Jeffrey SS
Année : 2021
Journal : Trends Mol Med

Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer.

Auteurs : Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber Rd, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, Mcfadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr
Année : 2021
Journal : N Engl J Med
Volume : 384
Pages : 2394-2405

Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.

Auteurs : Chang CA, Jen J, Jiang S, Sayad A, Mer AS, Brown KR, Nixon AML, Dhabaria A, Tang KH, Venet D, Sotiriou C, Deng J, Wong KK, Adams S, Meyn P, Heguy A, Skok JA, Tsirigos A, Ueberheide B, Moffat J, Singh A, Haibe-Kains B, Khodadadi-Jamayran A, Neel BG
Année : 2021
Journal : Cancer Discov

Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features.

Auteurs : Raffenne J, Martin FA, Nicolle R, Konta M, Blum Y, Torrisani J, Puleo F, Bachet JB, Svrcek M, Bardier-Dupas A, Emile JF, Demetter P, Radman M, Van Laethem JL, Hammel P, Rebours V, Paradis V, Couvelard A, Cros J
Année : 2021
Journal : Cancers (Basel)
Volume : 13

Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial.

Auteurs : Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P, Senti C, Reina EA, Van Bogaert C, Deleporte A, Geboes K, Delaunoit T, Demolin G, Peeters M, DHondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Vergauwe P, Van Laethem JL, Flamen P, Hendlisz A, Sclafani F
Année : 2021
Journal : Clin Colorectal Cancer

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

Auteurs : Piccart-Gebhart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pienkowski T, Toi M, Wilcken N, Andersson M, Im YH, Tseng LM, Lueck HJ, Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber Rd, Viale G, Thomssen C
Année : 2021
Journal : J Clin Oncol
Volume : 39
Pages : 1448-1457

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.

Auteurs : Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, OShaughnessy J, Cortes J, Tsai M, Vahdat L, Diéras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA
Année : 2021
Journal : Ann Oncol
Volume : 32
Pages : 1148-1156

Results of a single-arm pilot study of <sup>32</sup>P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy.

Auteurs : Ross PJ, Wasan HS, Croagh D, Nikfarjam M, Nguyen N, Aghmesheh M, Nagrial AM, Bartholomeusz D, Hendlisz A, Ajithkumar T, Iwuji C, Wilson NE, Turner DM, James DC, Young E, Harris MT
Année : 2021
Journal : ESMO Open
Volume : 7
Pages : 100356

Pancreatic Cancer Meets Human Microbiota: Close Encounters of the Third Kind.

Auteurs : Arsenijevic T, Nicolle R, Bouchart C, DHaene N, Demetter P, Puleo F, Van Laethem JL
Année : 2021
Journal : Cancers (Basel)
Volume : 13

Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology.

Auteurs : Castelo-Branco L, Awada A, Pentheroudakis G, Perez-Gracia JL, Mateo J, Curigliano G, Banerjee S, Giuliani R, Lordick F, Cervantes A, Tabernero J, Peters S
Année : 2021
Journal : ESMO Open
Volume : 6
Pages : 100237

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors.

Auteurs : Spicer J, Marabelle A, Baurain JF, Jebsen NL, Jøssang DE, Awada A, Kristeleit R, Loirat D, Lazaridis G, Jungels C, Brunsvig P, Nicolaisen B, Saunders A, Patel H, Galon J, Hermitte F, Camilio KA, Mauseth B, Sundvold V, Sveinbjørnsson B, Rekdal Ø
Année : 2021
Journal : Clin Cancer Res
Volume : 27
Pages : 2755-2763

Targeted agents in older patients with gastrointestinal cancers - An overview.

Auteurs : Monteiro AR, Conde RS, Basto R, Sclafani F, Deleporte A, Hendlisz A, Dal Lago L
Année : 2021
Journal : J Geriatr Oncol
Volume : 12
Pages : 1240-1252

Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey.

Auteurs : Cufer T, Kosty M, Osterlund P, Jezdic S, Pyle D, Awada A, Close J, El-Saghir N, Lordick F, Rutkowski P, Tfayli A, Wildiers H
Année : 2021
Journal : ESMO Open
Volume : 6
Pages : 100219

High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer.

Auteurs : Bareche Y, Pommey S, Carneiro M, Buisseret L, Cousineau I, Thebault P, Chrobak P, Communal L, Allard D, Robson SC, Mes-Masson AM, Provencher D, Lapointe R, Stagg J
Année : 2021
Journal : J Immunother Cancer
Volume : 9

Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients.

Auteurs : Rothé F, Lambertini M, Goldrat O, Maetens M, Bareche Y, Blanc J, Rouas G, Larsimont D, Sotiriou C, Ignatiadis M, Demeestere I
Année : 2021
Journal : Front Oncol
Volume : 11
Pages : 686625

Outcomes and Prognostic Factors in a Large Cohort of Hospitalized Cancer Patients With COVID-19.

Auteurs : Nader Marta G, Colombo Bonadio R, Nicole Encinas Sejas O, Watarai G, Mathias Machado MC, Teixeira Frasson L, Motta Venchiarutti Moniz C, de Luca Ito RK, Peixoto D, Oliveira Hoff C, Menegatti Anastacio V, Ribeiro U Jr, Pereira J, Rocha V, Abdala E, Del Pilar Estevez-Diz M, Hoff PM
Année : 2021
Journal : JCO Glob Oncol
Volume : 7
Pages : 1084-1092